Company / R&D per Share
Enovis R&D per Share History
FY2021-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D per Share
$2.10
FY2025
5-year range
$0.41 / $2.10
FY2021-FY2025
Trend
+25.8%
vs FY2024
Sector context
#44 of 108
Health Care
What the data says
At $2.10, Enovis's r&d per share ranks #44 of 108 in the Health Care sector. R&D per Share has increased for 4 consecutive years, from $0.41 in FY2021 to $2.10 in FY2025.
Based on SEC 10-K filings.
2.10 in FY2025 with a 3-year CAGR of +47.3%.
Improved from $0.91 to $2.10 over the past 2 years.
Health Care sector context is included.
R&D per Share over time
Growth rates
- 3-Year CAGR
- +47.3%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#44 of 108 in Health CareTop 41% of 108This company $2.10 Sector average $2.07
▼
+1.6% above sector average
Key checks
Key Insights
- Enovis's r&d per share has grown for 4 consecutive years.
- In FY2025, r&d per share increased 25.8% year-over-year.
- Ranks #44 out of 108 companies in the Health Care sector.
- Lowest r&d per share in the period was in FY2021.
Company context
Key Data Points
- Altman Z-Score -0.27 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $2.10 | +25.8% |
| FY2024 | $1.67 | +84.7% |
| FY2023 | $0.91 | +37.6% |
| FY2022 | $0.66 | +58.8% |
| FY2021 | $0.41 | - |
| FY2020 | - | - |
| FY2019 | - | - |
| FY2018 | - | - |
| FY2017 | - | - |
| FY2016 | - | - |
As of FY2025 · SEC 10-K · Updated Jul 2, 2026